CYTEIR THERAPEUTICS INC (CYT) Stock News

USA - NASDAQ:CYT - US23284P1030 - Common Stock

3.02 USD

-0.07 (-2.27%)

Last: 3/15/2024, 8:00:01 PM

3.1 USD

+0.08 (+2.65%)

After Hours: 3/15/2024, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CYT Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: Cyteir Therapeutics

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

2 years ago - By: Cyteir Therapeutics

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

2 years ago - By: Benzinga - Mentions: ROOT BXRX RNLX UNCY ...

Nasdaq Jumps 200 Points; Baudax Bio Shares Spike Higher

3 years ago - By: Benzinga - Mentions: NVS SENS LYEL QSI

5 Value Stocks In The Healthcare Sector

2 years ago - By: Bloomberg

Biotech’s Drug Flop Turns Into Boon for Investors on Cash Return

2 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution

2 years ago - By: Cyteir Therapeutics

Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Clinical Activity and Generally Well Tolerated Safety Profile

2 years ago - By: Cyteir Therapeutics, Inc.

Cyteir Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

3 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

3 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer

3 years ago - By: Seeking Alpha

Cyteir Therapeutics downgraded to neutral at BofA on pipeline prioritization (NASDAQ:CYT)

3 years ago - By: Seeking Alpha

Cyteir Therapeutics (NASDAQ:CYT) to prioritize development of CYT-0851

3 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway

3 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Reports Third Quarter 2022 Financial Results and Operational Highlights

3 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Presents Poster on the Identification of Mechanism of Action of CYT-0851 at the 34th Annual EORTC-NCI-AACR Symposium

3 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

3 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Reports Second Quarter 2022 Financial Results and Operational Highlights

3 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference

3 years ago - By: Cyteir Therapeutics

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

3 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

4 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Reports First Quarter 2022 Financial Results and Operational Highlights

4 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics to Participate in the 2022 Bank of America Healthcare Conference

4 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

4 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics Names Adam Veness General Counsel

4 years ago - By: Cyteir Therapeutics

Cyteir Therapeutics to Host Virtual Research and Development (R&D) Day on April 26, 2022